Education
About Us
Working with TipRanks
Follow Us
Pharming Group (PHAR)
NASDAQ:PHAR
PHAR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.73 - $12.61
Previous CloseN/A
Volume181.00
Average Volume (3M)5.36K
Market Cap
$735.83M
Enterprise Value$744.24M
Total Cash (Recent Filing)$128.73M
Total Debt (Recent Filing)$128.33M
Price to Earnings (P/E)―
Beta0.43
Next Earnings
Nov 06, 2025EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding68,514,760
10 Day Avg. Volume8,196
30 Day Avg. Volume5,355
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue2.18
Enterprise Value/Gross Profit2.44
Enterprise Value/Ebitda24.47
Forecast
1Y Price Target
$30.50Price Target Upside144.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
EarningsPharming posted an EPS of $0.006, surpassing the estimate of ($0.025), and reported total quarterly revenue of $93.2 million against an estimated $83.26 million.
Product ExpansionResearch indicates potential expansion of Joenja's addressable market by reclassifying VUS patients, which could drive new growth.
Revenue GrowthRuconest revenue exceeded expectations, coming in at $80.4 million compared to the estimated $70.64 million.
Bears Say
Executive ChangesThe departure of CFO Mr. Joroen Wakkerman could introduce uncertainty during Pharming's expansion phase.
Risk FactorsPotential risks to reaching price targets include lack of market penetration and challenges in securing adequate funding.
Pharming Group News
PHAR FAQ
What was Pharming Group’s price range in the past 12 months?
Pharming Group lowest stock price was $6.73 and its highest was $12.61 in the past 12 months.
What is Pharming Group’s market cap?
Pharming Group’s market cap is $735.83M.
When is Pharming Group’s upcoming earnings report date?
Pharming Group’s upcoming earnings report date is Nov 06, 2025 which is in 92 days.
How were Pharming Group’s earnings last quarter?
Pharming Group released its earnings results on Jul 31, 2025. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of -$0.105 by $0.165.
Is Pharming Group overvalued?
According to Wall Street analysts Pharming Group’s price is currently Undervalued.
Does Pharming Group pay dividends?
Pharming Group does not currently pay dividends.
What is Pharming Group’s EPS estimate?
Pharming Group’s EPS estimate is <0.01.
How many shares outstanding does Pharming Group have?
Pharming Group has 68,514,760 shares outstanding.
What happened to Pharming Group’s price movement after its last earnings report?
Pharming Group reported an EPS of $0.06 in its last earnings report, beating expectations of -$0.105. Following the earnings report the stock price went up 10.109%.
Which hedge fund is a major shareholder of Pharming Group?
Currently, no hedge funds are holding shares in PHAR
Pharming Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.50 (144.39% Upside)
$30.50 (144.39% Upside)
Blogger Sentiment
Bullish
PHAR Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 7.2%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.96%
12-Months-Change
Fundamentals
Return on Equity
-3.40%
Trailing 12-Months
Asset Growth
7.29%
Trailing 12-Months
Company Description
Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
PHAR Company Deck
PHAR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was largely positive, driven by strong revenue growth and successful product performance from RUCONEST and Joenja. Despite some challenges in operating expenses and patient reclassification, the company has increased its revenue guidance and is making progress in its pipeline expansion, indicating a strong overall outlook.Read More>PHAR Stock 12 Month Forecast
Average Price Target
$30.50
▲(144.39%Upside)
Technical Analysis
KalVista Pharmaceuticals
―
AnaptysBio
―
Dianthus Therapeutics
―
Trevi Therapeutics
―
Immunome
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.08% Other Institutional Investors
99.92% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---